Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 31 - Medicinal preparations containing organic active ingredients
Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
05/2014
05/22/2014US20140141060 Compositions and methods for protecting cells during cancer chemotherapy and radiotherapy
05/22/2014US20140141059 Patch
05/22/2014US20140141058 Use of oligosaccharide compounds for the prevention and treatment of pathological scars
05/22/2014US20140141056 Lidocaine-containing hydrogel patch
05/22/2014US20140141055 Manufacturing of semi-plastic pharmaceutical dosage units
05/22/2014US20140141040 Avirulent, immunogenic flavivirus chimeras
05/22/2014US20140141000 Bispecific EGFR/C-Met Antibodies
05/22/2014US20140140997 Methods of Treating Retroviral Infections in Felines
05/22/2014US20140140993 Combinations of an anti-her2 antibody-drug conjugate and chemotherapeutic agents, and methods of use
05/22/2014US20140140991 Methods of treating a disease or disorder associated with bruton's tyrosine kinase
05/22/2014US20140140988 Combination therapy of an afucosylated cd20 antibody with a mdm2 inhibitor
05/22/2014US20140140982 Selective serotonin 2a/2c receptor inverse agonists as therapeutics for neurodegenerative diseases
05/22/2014US20140140979 Compositions And Methods Of Use of Phorbol Esters For Treatment of Stroke
05/22/2014US20140140977 Methods and Kits for Assessing Heparanase Procoagulant Activity, Compositions Comprising Heparanase, and Methods for the Treatment of Coagulation Related Disorders
05/22/2014US20140140974 Solubilized CoQ-10
05/22/2014US20140140970 Use of Secretor, Lewis and Sialyl Antigen Levels in Clinical Samples as Predictors of Risk for Disease
05/22/2014US20140140958 Spiro[2.4]heptanes for Treatment of Flaviviridae Infections
05/22/2014US20140140957 Spiro[2.4]heptanes for Treatment of Flaviviridae Infections
05/22/2014US20140140956 Biaryl derivatives as bromodomain inhibitors
05/22/2014US20140140955 Substituted purine nucleosides, phosphoroamidate and phosphorodiamidate derivatives for treatment of viral infections
05/22/2014US20140140953 Salts of bicyclo-substituted pyrazolon azo derivatives, preparation method and use thereof
05/22/2014US20140140952 D-Alanine Ester of Sp-Nucleoside Analog
05/22/2014US20140140951 D-Alanine Ester of Rp-Nucleoside Analog
05/22/2014US20140140946 Skin preparation composition for external use with excellent antibacterial and antifungal effects
05/22/2014US20140140942 Pharmaceutical composition for administration to nails
05/22/2014US20140140937 Foamable Benzoyl Peroxide Compositions for Topical Administration
05/22/2014US20140140932 Functionalized Magnetic Nanoparticles and Use in Imaging Amyloid Deposits and Neurofibrillary Tangles
05/22/2014DE102012221219A1 Verfahren zur Vergrößerung der Partikelgröße kristalliner Wirkstoff-Mikropartikel A process for increasing the particle size of crystalline drug microparticles
05/22/2014CA2851130A1 A pharmaceutical composition used for reducing damage caused by free radicals
05/21/2014EP2733205A1 Corticospinal upper motor neurons, methods and compositions for differentiating neural stem cells by modulating CB1 cannabinoid receptor signaling and uses thereof
05/21/2014EP2733146A1 Thioether derivatives as protein kinase inhibitors
05/21/2014EP2733144A1 Novel compound having parp inhibitory activity
05/21/2014EP2733143A1 Substituted pyrazolo[3,4-d]pyrimidine compounds, their preparation and use as sigma receptors ligands
05/21/2014EP2733141A1 Azabenzimidazole derivative having ampk-activating activity
05/21/2014EP2733140A1 Indirubin derivative having highly selective cytotoxicity for malignant tumors
05/21/2014EP2732821A1 Amphoteric polyamidoamines in the treatment of malaria
05/21/2014EP2732820A1 Selective androgen receptor modulators for treating cancer
05/21/2014EP2732819A2 Compounds that enhance Atoh-1 expression
05/21/2014EP2732818A1 A diphenylsulfonamide endothelin and angiotensin II receptor agonist to treat glomerulosclerosis
05/21/2014EP2732817A1 A compound for use in treating injury associated with exposure to phosgene or chlorine gas
05/21/2014EP2732816A1 Use of amidoxime carboxylic acid esters and n-hydroxyguanidine carboxylic acid esters for producing prodrugs
05/21/2014EP2732815A1 Modulators of intracellular chloride concentration for treating fragile X syndrome
05/21/2014EP2732813A1 Orodispersible film compositions
05/21/2014EP2732812A1 Pramipexole retard tablet formulation
05/21/2014EP2732811A1 Method for producing a freeze-dried compound
05/21/2014EP2732810A1 Spherical particles of clopidogrel bisulfate, pharmaceutical composition including same, and method for manufacturing same
05/21/2014EP2732036A2 Compositions comprising agents that inhibit neuropilin and tolloid like 2
05/21/2014EP2731971A1 MODULATORS OF THE NLRP3 INFLAMMASOME IL-1ß PATHWAY FOR THE PREVENTION AND TREATMENT OF ACNE
05/21/2014EP2731953A1 Tricyclic inhibitors of kinases useful for the treatment of proliferative diseases
05/21/2014EP2731952A1 Radiolabelled rotenone derivatives and their use in spect imaging
05/21/2014EP2731951A1 4-oxo-3,5,7,8-tetrahydro-4h-pyrano {4,3-d} pyrminidinyl compounds for use as tankyrase inhibitors
05/21/2014EP2731950A1 Azetidine derivatives for treatment of melanin related disorders
05/21/2014EP2731948A1 Novel substituted indole derivatives as gamma secretase modulators
05/21/2014EP2731947A1 Substituted quinazolines, the preparation thereof and the use thereof in pharmaceutical compositions
05/21/2014EP2731946A1 Salts of aza-bicyclic di-aryl ethers and methods to make them or their precursors
05/21/2014EP2731945A1 N- (6- ( (2r,3s) -3,4-dihydroxybutan-2-yloxy) -2- (4 - fluorobenzylthio) pyrimidin- 4 - yl) -3- methylazetidine- 1 - sulfonamide as chemokine receptor modulator
05/21/2014EP2731944A1 Gpr 119 modulators
05/21/2014EP2731942A1 Novel 2-piperidin-1-yl-acetamide compounds for use as tankyrase inhibitors
05/21/2014EP2731941A1 Novel and selective ccr2 antagonists
05/21/2014EP2731940A1 4 - piperidinyl compounds for use as tankyrase inhibitors
05/21/2014EP2731939A1 New crystalline form
05/21/2014EP2731938A1 Novel anti-cancer isocarbostyril alkaloid conjugates
05/21/2014EP2731932A1 Aminomethyl quinolone compounds
05/21/2014EP2731931A1 Polycyclic pyrrolidine-2,5-dione derivatives as -formyl peptide receptor like-1 (fprl-1) receptor modulators
05/21/2014EP2731924A1 Terpene analogues and uses thereof for treating neurological conditions
05/21/2014EP2731676A1 Novel fxr (nr1h4) binding and activity modulating compounds
05/21/2014EP2731636A2 Lotions derived from renewable resources and absorbent articles comprising same
05/21/2014EP2731627A1 Oral compositions comprising an antacid, an anaesthetic and an inorganic matrix comprising silicon dioxide and titanium dioxide
05/21/2014EP2731617A1 Lipid-containing psa compositions, methods of isolation and methods of use thereof
05/21/2014EP2731616A1 Method for the prevention and treatment of sepsis
05/21/2014EP2731615A2 Method and apparatus for the production of an arabinoxylan-enriched preparation and other co-products
05/21/2014EP2731614A1 Combination treatment for cancer
05/21/2014EP2731613A1 Treatment of excessive menstrual bleeding associated with uterine fibroids
05/21/2014EP2731612A2 Inhibitors of bruton's tyrosine kinase
05/21/2014EP2731611A2 Combination als therapy
05/21/2014EP2731610A2 Pharmaceutical combination
05/21/2014EP2731609A1 Nicotinamide compositions and the therapeutic use thereof
05/21/2014EP2731608A2 Inhibitors of bacterial type iii secretion system
05/21/2014EP2731607A1 Method for timing a colonoscopy wherein a picosulate composition is administered
05/21/2014EP2731606A1 Gel compositions of oxymetazoline and methods of use
05/21/2014EP2731605A2 Pharmaceutical compositions for rectal administration
05/21/2014EP2731604A1 Use of coumarin derivatives for the preparation of drugs for treating skin diseases
05/21/2014EP2731603A1 Stable dosage forms of arterolane and piperaquine
05/21/2014EP2731602A1 Treatment for hypoxia
05/21/2014EP2731601A2 Eosinophil peroxidase compositions and methods of their use
05/21/2014EP2731600A2 Inhibitors of bacterial type iii secretion system
05/21/2014EP2731599A1 Compositions and methods for modulating metabolic pathways
05/21/2014EP2731598A2 Aliskiren hemifumarate, crystal form and amorphous solid
05/21/2014EP2731597A2 Methods for treating inflammation and hypertension with gamma-ketoaldehyde skavengers
05/21/2014EP2731596A2 Combined therapeutic agent
05/21/2014EP2731595A1 Use of xanthophyll carotenoids to improve visual performance and neural efficiency
05/21/2014EP2731594A1 Capsule formulation comprising montelukast and levocetirizine
05/21/2014EP2731593A2 A composition, device and method for delayed and sustained release of brain energy molecules
05/21/2014EP2731592A1 Controlled release pharmaceutical composition of non-ergoline dopamine agonist
05/21/2014EP2731591A2 Liposomes co-encapsulating a bisphosphonate and an amphipathic agent
05/21/2014EP2731589A1 A new therapeutical composition containing apomorphine as active ingredient
05/21/2014EP2731588A1 Composition and method for treating hpv
05/21/2014EP2731587A1 Intravaginal delivery system
05/21/2014EP2731586A1 Formulations of amikacin and fosfomycin combinations and methods and systems for treatment of ventilator associated pneumonia (vap) and ventilator associated tracheal (vat) bronchitis
05/21/2014EP2731585A1 Cosmetic and/or dermatological use of oligosaccharide compounds for preventing and treating stretch marks
1 ... 261 262 263 264 265 266 267 268 269 270 271 272 273 274 275 276 277 278 279 280 281 ... 7860